Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894, September 2000

Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?☆☆☆

An evaluation of the risks and benefits of TPA from the patient's perspective

  • Daren K Heyland

      Affiliations

    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Angada 3, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7. Tel: 613-549-6666x3339; fax: 613-548-2577.
    • ,
  • Amiram Gafni

      Affiliations

    • Center for Health Economics and Policy Analysis and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Mitchell A.H Levine

      Affiliations

    • Center for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada

Received 27 August 1998; received in revised form 16 July 1999; accepted 28 October 1999.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Dr. Heyland is a Career Scientist with the Ministry of Health of Ontario. This Study not funded.

☆☆ Evaluation Study as of July 3, 1999.

PII: S0895-4356(99)00214-0

Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894, September 2000

Article Tools

* Image Usage & Resolution